Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 1998

View Archived Issues

Company Profile: Nortran

Dura: Q4 and FY 1997 highlights

Antifibrotic compounds discovered at Hoechst

TIMI 12 trial results published

Heterocyclic bradykinin antagonists from Hoechst

Hoechst reveals several series of Na+/H+ exchange inhibitors

Name change and relocation announced

Beneficial effects of vitamin C demonstrated in heart failure patients

Strategies for purging latently infected cells in HIV-positive patients studied at NIAID

NexMed completes phase I trial of ED product

Phase III trial compares immediate and delayed treatment with fomivirsen for CMV retinitis

New targets for stroke: neurotrophic growth factors

PRO-2000 gel well tolerated in phase I trial in healthy females

Preclinical studies support potential of CP-358774 as cancer treatment

StressGen licenses heat shock transcription factors

Neuroprotective effects of IL-1ra

Glaxo Wellcome characterizes in vitro/in vivo antibacterial activity of new trinem

Neuroprotective activity described for CoCensys neurosteroid

Pharmacia & Upjohn and Chiron establish HCV collaboration

Zeneca receives patent protection for new Diprivan formulation

New formulation of enalapril now available in U.K.

Promising preclinical results reported for Resolve

Potent SK(Ca) channel blocker prepared by European university researchers

Asacard approved in U.K.

Continued HIV suppression requires triple drug maintenance therapy

AVI BioPharma on the way to finalizing ImmunoTherapy acquisition

Abgenix and Schering-Plough collaborate on XenoMouse antibodies

FDA issues approvable letter for BioLon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...